102,094 Shares in Korro Bio, Inc. (NASDAQ:KRRO) Purchased by Woodline Partners LP

Woodline Partners LP bought a new position in shares of Korro Bio, Inc. (NASDAQ:KRRO - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 102,094 shares of the company's stock, valued at approximately $3,887,000. Woodline Partners LP owned 1.09% of Korro Bio at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Deep Track Capital LP increased its position in Korro Bio by 2.9% during the fourth quarter. Deep Track Capital LP now owns 874,614 shares of the company's stock worth $33,297,000 after acquiring an additional 24,614 shares during the period. Alliancebernstein L.P. bought a new stake in Korro Bio in the 4th quarter valued at $26,870,000. Driehaus Capital Management LLC increased its holdings in Korro Bio by 220.3% in the 4th quarter. Driehaus Capital Management LLC now owns 494,905 shares of the company's stock valued at $18,841,000 after buying an additional 340,410 shares during the period. Point72 Asset Management L.P. increased its holdings in Korro Bio by 11.0% in the 4th quarter. Point72 Asset Management L.P. now owns 493,997 shares of the company's stock valued at $18,806,000 after buying an additional 49,147 shares during the period. Finally, Tri Locum Partners LP increased its holdings in Korro Bio by 125.3% in the 4th quarter. Tri Locum Partners LP now owns 144,216 shares of the company's stock valued at $5,490,000 after buying an additional 80,202 shares during the period. Institutional investors own 13.18% of the company's stock.

Korro Bio Price Performance

Shares of KRRO traded down $0.29 during trading hours on Friday, hitting $11.45. The stock had a trading volume of 22,370 shares, compared to its average volume of 99,986. The company's fifty day moving average is $15.36 and its two-hundred day moving average is $29.64. Korro Bio, Inc. has a 52 week low of $11.13 and a 52 week high of $98.00. The stock has a market capitalization of $107.48 million, a price-to-earnings ratio of -1.21 and a beta of 2.66.

Korro Bio (NASDAQ:KRRO - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported ($2.49) earnings per share for the quarter, topping the consensus estimate of ($2.60) by $0.11. The firm had revenue of $2.55 million during the quarter, compared to the consensus estimate of $0.13 million. Equities analysts predict that Korro Bio, Inc. will post -9.52 EPS for the current fiscal year.

Analyst Ratings Changes

KRRO has been the topic of several analyst reports. Chardan Capital reissued a "buy" rating and issued a $25.00 price target on shares of Korro Bio in a report on Tuesday, May 13th. Cantor Fitzgerald raised shares of Korro Bio to a "strong-buy" rating in a report on Tuesday, April 29th. HC Wainwright lowered their price target on shares of Korro Bio from $115.00 to $100.00 and set a "buy" rating on the stock in a report on Thursday, May 8th. Royal Bank of Canada lowered their price target on shares of Korro Bio from $105.00 to $95.00 and set an "outperform" rating on the stock in a report on Wednesday, March 19th. Finally, Oppenheimer lowered their price target on shares of Korro Bio from $155.00 to $90.00 and set an "outperform" rating on the stock in a report on Tuesday, May 13th. Five investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Korro Bio has an average rating of "Buy" and a consensus target price of $102.43.

About Korro Bio

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).